English English Spanish Spanish

News & Events

December 5, 2022
December 5, 2022

Lecanemab Represents Promising Therapy for Alzheimer Disease
By: hlr
View Article
December 1, 2022
December 1, 2022

Dr. Sharon Cohen Discusses Alzheimer’s in Canada on the Social CTV
By: hlr
View Article
November 10, 2022
November 10, 2022

Headlands Research CEO Mark Blumling Joins SCRS Talks to Discuss Collaborating for Site Sustainability: The Ins & Outs of Site Networks
By: hlr
View Article
November 3, 2022
November 3, 2022

First Patient Dosed in Clairvoyant’s Phase 2 Clinical Trial Exploring Psilocybin as a Treatment for Alcohol Use Disorder
By: hlr
View Article
June 30, 2022
June 30, 2022

Headlands Research Further Expands its Leading Clinical Research Site Network by Acquiring Peninsula Research Associates
By: hlr
View Article
May 25, 2022
TMP Press Release
May 25, 2022

Headlands Research’s Toronto Memory Program site and RetiSpec Awarded Grant to Launch Innovative Early Detection Program for Alzheimer’s
By: hlr
View Article
May 24, 2022
Headlands Research Brownsville
May 24, 2022

Groundbreaking Headlands Research and Pfizer Partnership to Significantly Improve Diversity in Clinical Trials
By: briancflms
View Article
October 14, 2021
Milken Institute
October 14, 2021

Headlands Research CEO Mark Blumling to Speak at Milken Institute Global Conference
By: hlr
View Article
June 16, 2021
June 16, 2021

Multi-Site Contributor Headlands Research Congratulates Biogen on FDA Approval of Aducanumab for Alzheimer’s Disease
By: hlr
View Article
April 13, 2021
icons of medical equipment
April 13, 2021

Wall Street Journal: Covid-19 Vaccine: How Private-Equity Portfolio Companies Played a Role
By: hlr
View Article